Q3 Revenue Tops $1M, Up Nearly 300% Year-Over-Year; Guidance Reaffirmed
RNXT sits 70% above its 52-week low of $0.701.
Summary
RenovoRx posted Q3 2026 revenue of $1.07 million versus $266,000 a year ago, a nearly 300% jump and 17% above Q2's record $909,000. Active commercial cancer center customers rose to 26 from 21 at the end of Q2, with management still targeting 36 by year-end. Full-year 2026 revenue guidance was maintained at $3.75 million to $4.25 million, which would more than triple 2025's $1.1 million. Cash stood at $10.4 million as of September 30, helped by $3.5 million from warrant exercises, and management says that funds operations into the second half of 2027. The quarter also brought the first commercial TAMP use beyond pancreatic cancer (a sarcoma patient) and the first patient treated in the PRISM-TAMP investigator-initiated trial at the University of Vermont. The offset: operating loss held at $3.2 million as SG&A nearly doubled to $2.9 million to build out the sales force, and net loss widened to $3.6 million. Phase III TIGeR-PaC top-line data is expected in the second half of 2027.
At the time of this announcement, RNXT was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.7M. The 52-week trading range was $0.70 to $2.59. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.